多中心分析:标准(放)化疗在老年局部晚期食管或胃食管结合部腺癌中的价值
这项多中心回顾性分析纳入86例≥65岁(中位73岁,范围65-92岁)的食管或胃食管结合部腺癌患者,2006至2020年在德国3家大型综合癌症中心接受根治性或新辅助(放)化疗。新辅助放化疗后手术与显著更好的PFS、DMFS和OS相关,但该优势未在根治性放化疗中见到;不适合手术的老年患者根治性放疗期间多数需省略或调整化疗。
要点
- 86例老年(≥65岁)食管或胃食管结合部腺癌患者接受根治性或新辅助(放)化疗,中位年龄73岁。
- 2年LRC、DMFS、PFS和OS分别为72%、49%、46%和52%。
- 新辅助放化疗后手术较所有非手术(根治性放疗和放化疗合并)显著改善PFS(p=0.006)、DMFS(p=0.006)和OS(p=0.004)。
核心结论
- 在作者的分析中,不适合手术的老年食管癌患者绝大多数在根治性放疗期间需要省略化疗或调整化疗剂量,因而导致PFS和OS降低。
- 作者认为需要优化非手术方案并识别老年(胃)食管腺癌患者安全接受同步化疗的潜在预测因素。
研究设计与样本
- 多中心回顾性分析,纳入86例≥65岁(中位年龄73岁,范围65-92岁)的食管或胃食管结合部腺癌患者,2006至2020年在德国3家大型综合癌症中心接受根治性或新辅助(放)化疗。
- 分析LRC、PFS、DMFS、OS及按CTCAE v5.0标准评估的治疗相关毒性,并评估可能与患者结局相关的参数。
主要发现
- 33例(38%)接受新辅助放化疗后手术,其余患者接受根治性(放)化疗。
- 80例(93%)能够在不降低放疗剂量下完成放疗。
- 66例(77%)最初处方同步化疗;治疗过程中48%(n=32)因治疗相关毒性和合并症需要化疗降级。
- 29例(34%)出现较高级别急性毒性,14例(16%)出现较高级别晚期毒性。
- 2年LRC、DMFS、PFS和OS分别为72%、49%、46%和52%。
关键数值与推荐
- 多因素分析显示,新辅助放化疗后手术与所有非手术(根治性放疗和放化疗合并)相比,PFS(p=0.006)、DMFS(p=0.006)和OS(p=0.004)显著更好。
- 新辅助放化疗后手术与根治性放化疗相比未见到上述优势。
- 新辅助治疗患者中多数接受无剂量降低的标准放化疗(n=24/33,73%)。
- 根治性放疗患者中仅62%(n=33/53)能接受同步化疗,且其中多数需要化疗减量或调整(n=23/33,70%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To assess the tolerability and oncological results of chemoradiation in elderly patients with locally advanced adenocarcinoma of the esophagus or gastroesophageal junction. METHODS: This multi-center retrospective analysis included 86 elderly patients (≥ 65 years) with esophageal or gastroesophageal junction adenocarcinoma (median age 73 years; range 65-92 years) treated with definitive or neoadjuvant (chemo)radiotherapy. The treatment was performed at 3 large comprehensive cancer centers in Germany from 2006 to 2020. Locoregional control (LRC), progression-free survival (PFS), distant metastasis-free survival (DMFS), overall survival (OS), and treatment-associated toxicities according to CTCAE criteria v5.0 were analyzed, and parameters potentially relevant to patient outcomes were evaluated. RESULTS: Thirty-three patients (38%) were treated with neoadjuvant chemoradiation followed by surgery, while the remaining patients received definitive (chemo)radiation. The delivery of radiotherapy without dose reduction was possible in 80 patients (93%). In 66 patients (77%), concomitant chemotherapy was initially prescribed; however, during the course of therapy, 48% of patients (n = 32) required chemotherapy de-escalation due to treatment-related toxicities and comorbidities. Twenty-nine patients (34%) experienced higher-grade acute toxicities and 14 patients (16%) higher-grade late toxicities. The 2-year LRC, DMFS, PFS, and OS amounted to 72%, 49%, 46%, and 52%, respectively. In multivariate analysis, neoadjuvant chemoradiation followed by surgery was shown to be associated with significantly better PFS (p = 0.006), DMFS (p = 0.006), and OS (p = 0.004) compared with all non-surgical treatments (pooled definitive radiotherapy and chemoradiation). No such advantage was seen over definitive chemoradiation. The majority of patients with neoadjuvant therapy received standard chemoradiotherapy without dose reduction (n = 24/33, 73%). In contrast, concurrent chemotherapy was only possible in 62% of patients undergoing definitive radiotherapy (n = 33/53), and most of these patients required dose-reduction or modification of chemotherapy (n = 23/33, 70%). CONCLUSIONS: In our analysis, omission of chemotherapy or adjustment of chemotherapy dose during definitive radiotherapy was necessary for the overwhelming majority of elderly esophageal cancer patients not eligible for surgery, and hence resulted in reduced PFS and OS. Therefore, optimization of non-surgical approaches and the identification of potential predictive factors for safe administration of concurrent chemotherapy in elderly patients with (gastro)esophageal adenocarcinoma is required.
引用
- Bostel T, Nikolaidou E, Wollschläger D, et al. Multicenter analysis on the value of standard (chemo)radiotherapy in elderly patients with locally advanced adenocarcinoma of the esophagus or gastroesophageal junction. Radiat Oncol. 2024. PMID: 38433231. doi:10.1186/s13014-024-02414-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。